Phase 2 Prostate Cancer Trial, Recruiting NCT07223385 Sponsor: Cedars-Sinai Medical Center Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT07223385
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have prostate cancer that is localised, very high risk, has spread to nearby lymph nodes, or has spread to other parts of the body (Stage IV).
  • People who are currently being treated with a type of hormone-based cancer therapy called an androgen receptor pathway inhibitor (ARPI), with plans to continue that treatment for at least 18 months.
  • People who are older than 65 with at least one heart or blood vessel risk factor, OR people aged 45 to 65 with at least two of the following risk factors: high blood pressure, high cholesterol, diabetes, a close male family member (father or brother) who had heart disease before age 55 or a close female family member (mother or sister) who had heart disease before age 65, or calcium deposits found in the heart arteries on a chest scan.
  • People with a general health and activity level that falls within a moderate range (confirm with trial site for what this means in practice).
  • People who are willing and able to give written consent and follow the requirements of the study.

Who may not be able to join:

  • People who have already received more than 6 months of the type of hormone-based cancer therapy (ARPI) mentioned above before joining the trial.
  • People who are already receiving ongoing care from a heart specialist with specific expertise in the heart-related risks of cancer treatments.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Katelyn Atkins, MD, PhD, Cedars-Sinai Medical Center

Phone: 13104232133

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cedars-Sinai Medical Center
Registry
ClinicalTrials.gov
Start date
1 August 2026
Est. completion
1 August 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of any CV medication Initiation and/or Change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov